Literature DB >> 8205474

AMPA-selective glutamate receptor subtype immunoreactivity in the entorhinal cortex of non-demented elderly and patients with Alzheimer's disease.

D M Armstrong1, M D Ikonomovic, R Sheffield, R J Wenthold.   

Abstract

The present work employed immunocytochemical techniques and examined the distribution and cytological features of the AMPA receptor subunits, GluR2/3 and GluR1 within the entorhinal cortex of non-demented elderly (NC), patients with neuropathological and clinical verification of Alzheimer's disease (AD) and patients without a clinical history of dementia yet exhibiting sufficient quantities of senile plaques to meet neuropathological criteria of Alzheimer's disease (HPND). In NC cases, GluR2/3-immunolabeled neurons were abundantly distributed throughout layers II, III, V and VI of the entorhinal cortex. In contrast, GluR1-positive cells were comparatively sparse in number and largely restricted to layers V and VI. In AD, GluR2/3- and GluR1-labeled neurons were markedly reduced. Similarly, adjacent Nissl-stained tissue sections revealed substantial cell loss in the entorhinal cortex thus providing a reasonable explanation for the loss of these receptor subunits. Importantly, a dramatic loss of GluR2/3- and GluR1-immunolabeled neurons is also observed in the HPND cases, although examination of Nissl-stained tissue sections reveals little if any evidence of cell loss. The latter data suggest that a 'down-regulation' of these receptor subunits occurs prior to the actual loss of these cells. Furthermore, we hypothesize that the decrease of specific AMPA receptor subunits may influence neuronal vulnerability via a mechanism involving increased intracellular calcium and the destabilization of intracellular calcium homeostasis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8205474     DOI: 10.1016/0006-8993(94)91732-9

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  17 in total

1.  Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunction.

Authors:  Melissa J Alldred; Karen E Duff; Stephen D Ginsberg
Journal:  Neurobiol Dis       Date:  2011-11-07       Impact factor: 5.996

Review 2.  Accumulation of nuclear DNA damage or neuron loss: molecular basis for a new approach to understanding selective neuronal vulnerability in neurodegenerative diseases.

Authors:  Ivona Brasnjevic; Patrick R Hof; Harry W M Steinbusch; Christoph Schmitz
Journal:  DNA Repair (Amst)       Date:  2008-05-23

3.  Gene expression levels assessed by CA1 pyramidal neuron and regional hippocampal dissections in Alzheimer's disease.

Authors:  Stephen D Ginsberg; Melissa J Alldred; Shaoli Che
Journal:  Neurobiol Dis       Date:  2011-07-28       Impact factor: 5.996

4.  Reduced levels of the tyrosine phosphatase STEP block β amyloid-mediated GluA1/GluA2 receptor internalization.

Authors:  Yongfang Zhang; Pradeep Kurup; Jian Xu; George M Anderson; Paul Greengard; Angus C Nairn; Paul J Lombroso
Journal:  J Neurochem       Date:  2011-09-21       Impact factor: 5.372

5.  Age-related loss of calcium buffering and selective neuronal vulnerability in Alzheimer's disease.

Authors:  David Riascos; Dianne de Leon; Alaina Baker-Nigh; Alexander Nicholas; Rustam Yukhananov; Jing Bu; Chuang-Kuo Wu; Changiz Geula
Journal:  Acta Neuropathol       Date:  2011-08-27       Impact factor: 17.088

Review 6.  Review: disruption of the postsynaptic density in Alzheimer's disease and other neurodegenerative dementias.

Authors:  Yuesong Gong; Carol F Lippa
Journal:  Am J Alzheimers Dis Other Demen       Date:  2010-09-21       Impact factor: 2.035

7.  Loss of functional GABA(A) receptors in the Alzheimer diseased brain.

Authors:  Agenor Limon; Jorge Mauricio Reyes-Ruiz; Ricardo Miledi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-12       Impact factor: 11.205

8.  Plasticity of glutamate and GABAA receptors in the hippocampus of patients with Alzheimer's disease.

Authors:  David M Armstrong; Roxanne Sheffield; Amanda J Mishizen-Eberz; Troy L Carter; Robert A Rissman; Katsuyoshi Mizukami; Milos D Ikonomovic
Journal:  Cell Mol Neurobiol       Date:  2003-10       Impact factor: 5.046

Review 9.  Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme.

Authors:  Evelin L Schaeffer; Wagner F Gattaz
Journal:  Psychopharmacology (Berl)       Date:  2008-02-19       Impact factor: 4.530

10.  Inhibition of calcineurin-mediated endocytosis and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors prevents amyloid beta oligomer-induced synaptic disruption.

Authors:  Wei-Qin Zhao; Francesca Santini; Robert Breese; Dave Ross; Xiaohua Douglas Zhang; David J Stone; Marc Ferrer; Matthew Townsend; Abigail L Wolfe; Matthew A Seager; Gene G Kinney; Paul J Shughrue; William J Ray
Journal:  J Biol Chem       Date:  2009-12-23       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.